ADRIAN ADAMS - 18 Aug 2021 Form 4 Insider Report for IMPEL NEUROPHARMA INC

Role
COB, CEO and President, Director
Signature
/s/ John Leaman, M.D. as attorney-in-fact
Issuer symbol
N/A
Transactions as of
18 Aug 2021
Net transactions value
+$279,790
Form type
4
Filing time
19 Aug 2021, 17:23:12 UTC
Previous filing
26 Jul 2021
Next filing
28 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMPL Common Stock Purchase $237,506 +17,203 $13.81 17,203 18 Aug 2021 Direct F1
transaction IMPL Common Stock Purchase $32,751 +2,197 +13% $14.91 19,400 18 Aug 2021 Direct F2
transaction IMPL Common Stock Purchase $9,532 +600 +3.1% $15.89 20,000 18 Aug 2021 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.61 to $14.435 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.69 to $15.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.81 to $15.91 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.